Wedbush Upgrades Zentalis to Outperform on Promising Ovarian Cancer Survival Data
Analysts upgraded Zentalis after DENALI Part 1b data showed median survival of 15.9 months in Cyclin E1-positive platinum-resistant ovarian cancer.
Analysts upgraded Zentalis after DENALI Part 1b data showed median survival of 15.9 months in Cyclin E1-positive platinum-resistant ovarian cancer.
The biotech’s initial JANX011 Phase 1 results in healthy volunteers triggered a sharp selloff as investors questioned near-term value and differentiation.
Foundayo cut breathing interruptions by as much as 43.8% in a late-stage sleep apnea trial, supporting a new major market for Lilly.
Shares of Abeona Therapeutics plunged after the company issued new stock for a Phase 3 EoE candidate and completed a $30 million PIPE.
Shares of Faeth Therapeutics plunged after Phase 2 endometrial cancer data hit the expected bar but failed to drive a re-rating of the stock.
CorMedix agrees to buy Heron Therapeutics’ assets, including ZYNRELEF, APONVIE, CINVANTI and SUSTOL, with $145M cash plus stock. Closing expected in Q1 2027.